Drug Pricing
Our work in Drug Pricing
-
New Schaeffer White Paper Offers Solutions to Ensure Greater Patient Access to Prescription Drugs
The researchers propose three strategies for mitigating negative impacts of the Inflation Reduction Act to ensure greater patient access, increased innovation and lower costs.
Categorized in -
Mitigating the Inflation Reduction Act’s Adverse Impacts on the Prescription Drug Market
This paper provides three recommendations to steer the potential effects of the IRA toward its goal of improving patient access while encouraging innovation.
Categorized in -
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans
Cancer treatment, pediatric population, and coverage restriction of the reference products are some of the most significant factors that are associated with biosimilar coverage decisions.
Categorized in -
Senate Finance Committee Explores Costly, Secretive Practices in the Drug Supply Chain
Karen Van Nuys testified at the hearing, calling transparency “an essential first step.”
-
Testimony on Pharmacy Benefit Managers and the Prescription Drug Supply Chain
Karen Van Nuys spoke to the Senate Finance Committee on March 30, 2023 about the role PBMs play in the pharmaceutical distribution system.
-
Ending Health Insurance for Generic Drugs Would Save Patients Money
Eliminating insurance for generics might make patients nervous at first, but the payoff would be stable and affordable prices.
Categorized in -
Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D
This paper examines how direct-to-consumer advertising (DTCA) for prescription drugs influences utilization by exploiting a large and plausibly exogenous shock to DTCA driven by the introduction of Medicare Part D.
Categorized in -
Eli Lilly Is Cutting Insulin Prices and Capping Copays at $35 – 5 Questions Answered
The drugmaker’s move responded to the growing competition that has shaken up the insulin market in recent years.
Categorized in -
Schaeffer Co-Director Testifies on PBMs at Senate Congressional Hearing
Erin Trish was part of a panel of witnesses called to testify before the Committee on Commerce, Science and Transportation.
-
Testimony on Bringing Transparency and Accountability to Pharmacy Benefit Managers
Erin Trish spoke at the Senate Committee on Commerce, Science, & Transportation on February 16, 2023 about the complex and influential role that PBMs play in the pharmaceutical distribution system.